



September 8, 2025

Company name: Pharma Foods International Co., Ltd.

Representative: Mujo Kim, President

(Securities code: 2929 Prime Market)

Inquiries: Seiyu Harada, General Manager of

Corporate Strategy Department (Telephone: +81-75-394-8600)

## Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ended July 2025

Pharma Foods International Co., Ltd. (the "Company") hereby announces that, in light of recent business performance trends, it has revised the consolidated full-year financial results forecast for the fiscal year ended July 31, 2025 (August 1, 2024 to July 31, 2025), which was originally announced on September 12, 2024, as set forth below.

## 1. Revision of Consolidated Results Forecast for the Fiscal Year Ended July 2025

|   | Net Sales   | Operating Profit | Ordinary<br>Profit | Net Income Attributable to Owners of the Parent | Earnings per<br>Share |
|---|-------------|------------------|--------------------|---|-----------------------|
|   | JPY million | JPY million      | JPY million        | JPY million                                     | ЈРҮ                   |
| Previous Forecasts (A)  | 65,000      | 2,000            | 2,300              | 1,600   | 57.00                 |
| Revised Forecasts (B)   | 65,200      | 2,300            | 2,500              | 350   | 12.17                 |
| Change (B-A)  | 200         | 300              | 200                | <b>▲</b> 1,250                                  | _                     |
| Change (%)  | 0.3%        | 15.0%            | 8.7%               | <b>▲</b> 78.1                                   | _                     |
| (Reference) Actual Consolidated Results for<br>the Previous Fiscal Year ended July 31, 2024 | 62,147      | 5,113            | 5,249              | 3,205   | 112.71                |

## 2. Reason for the Revision

For the fiscal year ended July 31, 2025, the Company focused on the sales of new products addressing unmet health needs, such as hair growth, intestinal health, and tinnitus, by fully leveraging product development resources cultivated through R&D and pharmaceutical manufacturing.

In particular, new pharmaceutical products sold by Meiji Yakuhin Co., Ltd. ("Meiji Yakuhin"), a consolidated subsidiary of the Company - including LACTRON Tablets, TENRAI SEIRYU Tablets, Shibora Night, and HEALTH PAN C Tablets 2000 - performed strongly in acquiring new customers, supported by proactive upfront investment in advertising. As a result, the number of regular mail-order customers increased significantly, reaching approximately 2.7 times the level at the end of the previous fiscal year.

While Meiji Yakuhin strengthened its upfront investments, the Company, on a standalone basis, prioritized advertising investments in higher-margin products, resulting in profit expected to exceed initial forecasts. However, after deducting corporate income taxes and other adjustments, net income attributable to owners of the parent in the

consolidated financial statements is expected to decline.

Note: The financial results forecasts contained in this document are based on information available as of the date of publication. Actual results may differ materially from these forecasts due to a variety of factors.